The Cancer Letter

Inside information on cancer research and drug development

Vol.
35
No.
10
October 26, 2012Oct 26, 2012
Free
DOWNLOAD THE PDF

Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

Two Phase II Trials Display Ramucirumab Potential Efficacy

Gene Variant Associated With 44 Percent Cancer Risk Reduction

Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant

HCT Survivors More Likely To Show Heart Disease Risk Factors

PV-10 Produces 51 Percent Response Rate in Phase II Trial

Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk

Three Studies Test Oncotype DX In Breast and Colon Cancers

NCI-Approved CTEP Trials For the Month of October

FDA Approves Abraxane And Alimta for NSCLC

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account